Clinical characteristics | The group A (n = 29) | The group B (n = 27) |
---|---|---|
Age (years) | 56.8 ± 12.3 | 56.3 ± 12.4 |
Sex (Male/Female) | 15/14 | 13/14 |
Body weight (kg) | 66.2 ± 16.3 | 67.2 ± 15.9 |
BMI (kg/m2) | 25.2 ± 3.6 | 25.4 ± 3.7 |
Waist Circumference (cm) | 93.55 ± 10.5 | 93.46 ± 10.4 |
duration of diabetes (years) | 15.6 ± 5.7 | 15.4 ± 6.2 |
Hypertention (+/−) | 22/7 | 21/6 |
Retinopathy(NDR/SDR/PDR) | 2/17/10 | 2/16/9 |
Nephropathy(Normo-/micro-/macroalbuminuria) | 6/14/9 | 5/14/8 |
CVD(−/+) | 5/24 | 5/22 |
α-glucosidase inhibitors(-/ +) | 2/27 | 1/26 |
Metformin (−/ +) | 13/16 | 14/13 |
Duration of insulin treatment (years) | 9.6 ± 3.4 | 9.4 ± 3.5 |
Total insulin dose (unit/day) | 68.6 ± 14.6 | 66.8 ± 13.9 |
Frequency of insulin injection (2-/3−/−4 times /d) | 17/8/4 | 16/7/4 |
HbA1c (%) | 9.3 ± 1.5 | 9.4 ± 1.4 |
FBG (mmol/L) | 11.4 ± 2.4 | 11.3 ± 2.6 |
P2BG (mmol/L) | 16.8 ± 4.4 | 17.0 ± 4.5 |
Triglyceride (mmol/L) | 3.26 ± 1.14 | 3.28 ± 1.16 |
Total Cholesterol (mmol/L) | 6.23 ± 1.41 | 6.19 ± 1.51 |
HDL-Cholesterol (mmol/L) | 1.04 ± 0.23 | 1.12 ± 0.21 |
LDL-Cholesterol (mmol/L) | 4.13 ± 1.01 | 4.20 ± 1.02 |
Serum C peptide (ng/ml) | 1.06 ± 0.68 | 1.06 ± 0.70 |
HMW adiponectin (μg/ml) | 3.12 ± 1.56 | 3.22 ± 1.54 |